|
|
|
|
Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral ...
Zogenix announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen SAN DIEGO, CA, USA | March 17, 2010 | Zogenix, Inc.("Zogenix"), a...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
Let the jobs come to you!Synergy Pharmaceuticals, Inc! (OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients...
|
|
|
::: Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients...
|
|
|
Novelos Therapeutics's Phase III lung cancer trial fails endpoints
(Datamonitor via COMTEX) Novelos Therapeutics, a biopharmaceutical company, has reported that primary and secondary endpoints were not met in the company's pivotal Phase III trial in advanced non-small cell lung cancer, or NSCLC, with its lead...
|
|
|
Medivation Reports Fourth Quarter and Year-End 2009 Financial Results and Provides Corporate Update
SAN FRANCISCO, March 15 /PRNewswire-FirstCall/ -- Medivation, Inc.(NASDAQ:MDVN) today provided a corporate update and reported its financial results for the year ended December 31, 2009. 'We are disappointed by the results of the Phase 3 CONNECTION ...
|
|
|
Antisoma Initiates Phase IIb Trial Of AS1411 In Acute Myeloid Leukaemia
Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that it has started a randomised, controlled, multi-territory, phase IIb trial of AS1411 in patients with acute myeloid leukaemia (AML).Dr Ursula Ney, Chief Operating Officer of Antisoma, said: 'AML...
|
|
|
Ovatech Reports Enrollment is Closed for Phase 2 Clinical Trial of Ovaprene Non-Hormonal Intravaginal Contraceptive Ring at New York Downtown Hospital (NYDH)
Ovatech Reports Enrollment is Closed for Phase 2 Clinical Trial of Ovaprene Non-Hormonal Intravaginal Contraceptive Ring at New York Downtown Hospital (NYDH) News source: Business Wire Ovatech, an emerging womens health-focused company,...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
Clinical Trials Update Breaking News News source: Business Wire Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa ...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral ..
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis Refer to a friend Marketwire 2010 SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/19/10 --...
|
|
|
NeoPharm, Inc. Announces Fourth Quarter And Full Year 2009 Financial Results
LAKE BLUFF, Ill.-- (BUSINESS WIRE) -- NeoPharm, Inc.(Other OTC: NEOL.PK), a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORK--(EON: Enhanced Online News)--Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic
BusinessWire - Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-...
Companies: Callisto Pharmaceuticals Inc (CLSP), Synergy Pharmaceuticals Inc (SGYP) Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORKSynergy Pharmaceuticals, Inc.(OTC BB:SGYP - News), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc.(OTC BB:SGYP - News), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation ...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation ...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation ...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORK - (Business Wire) Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals, Inc.(OTC BB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients...
|
|
|
Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation ...
|
|
|
Novelos Therapeutics's Phase III lung cancer trial fails endpoints
Novelos Therapeutics, a biopharmaceutical company, has reported that primary and secondary endpoints were not met in the company's pivotal Phase III trial in advanced non-small cell lung cancer, or NSCLC, with its lead product, NOV-002, in...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic L
This Phase IIa EOE clinical trial is a double-blind, randomized, placebo-controlled, three-period crossover, pharmacokinetic and pharmacodynamic study of CK-2017357 in male and female patients with ALS.At least 36 and up to 72 patients may...
|
